Specialty Pharmaceutical Company dedicated to patients living with chronic conditions

Date Title Document
June 09, 2014 BioDelivery Sciences Receives FDA Approval for BUNAVAIL™ (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence
June 06, 2014 BioDelivery Sciences Receives FDA Approval for BUNAVAIL™ (buprenorphine and naloxone) Buccal Film for the Maintenance Treatment of Opioid Dependence
May 08, 2014 BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2014 Financials
May 08, 2014 BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
May 06, 2014 BioDelivery Sciences Announces Randomization of Over 50% of Subjects in its Initial Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy
April 07, 2014 BioDelivery Sciences Announces Four BUNAVAIL Abstracts to be Presented at the 2014 American Society of Addiction Medicine Annual Conference
April 03, 2014 BioDelivery Sciences Announces Enrollment of the First Patient in a Phase 3 Clinical Study of Clonidine Topical Gel for Painful Diabetic Neuropathy
March 27, 2014 BioDelivery Sciences Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the U.S.
March 14, 2014 BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report
March 05, 2014 BioDelivery Sciences to Present at the 26th Annual ROTH Conference
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
Thank you. We will get back to you soon